Abstract
Background
As several factors can contribute to low bone mineral density (BMD), we investigated the role of vitamin D in low BMD while controlling for other risk factors in inflammatory bowel diseases (IBD) patients.
Methods
We conducted a prospective cross-sectional study between 2008 and 2012 in adult IBD patients. Demographic data including age, gender, ethnicity, BMI, along with disease type and location, vitamin D levels, prior corticosteroid use, and anti-TNF use were recorded and evaluated with DEXA results.
Results
A total of 166 patients [105 Crohn’s disease (CD), 61 ulcerative colitis (UC)] qualified for the study. Low BMD was found in 40 %, twice as frequently in CD than in UC (p = 0.048). Higher prevalence of low BMD was associated with those of male gender (p = 0.05), Asian ethnicity (p = 0.02), and history of corticosteroid use (p = 0.001). Age, body mass index, or disease location did not increase the risk of low BMD. The overall prevalence of low vitamin D was 60 %, with insufficiency (25-hydroxy levels between 20 and 30 ng/mL) found in 37 % and deficiency (levels <20 ng/mL) found in 23 % of the patients. Vitamin D insufficient and deficient patients were two times (p = 0.049) and almost 3 times (p = 0.02) as likely to have low BMD, respectively.
Conclusions
Low vitamin D, male gender, Asian ethnicity, CD, and corticosteroid use significantly increased the risk of having low BMD, while age and disease location did not affect BMD in our IBD population. It remains important to evaluate for vitamin D nutritional deficiency and limit corticosteroid use to help prevent low BMD in IBD patients.
Similar content being viewed by others
References
Kornbluth A, Hayes M, Feldman S, et al. Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines’ criteria. Am J Gastroenterol. 2006;101:1546–1550.
Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. Ann Intern Med. 2000;133:795–799.
Tilg H, Moschen AR, Kaser A, et al. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut. 2008;57:684–694.
Pollak RD, Karmeli F, Eliakim R, et al. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93:1483–1490.
Kim HJ. New understanding of glucocorticoid action in bone cells. BMB Rep 2010;524–529.
Bernstein CN, Bector S, Leslie WD. Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease. Am J Gastroenterol. 2003;98:2468–2473.
Leslie WD, Miller N, Rogala L, et al. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol. 2008;103:1451–1459.
Jahnsen J, Falch JA, Mowinckel P, et al. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol. 2002;37:192–199.
Targownik LE, Leslie WD, Carr R, et al. Longitudinal change in bone mineral density in a population-based cohort of patients with inflammatory bowel disease. Calcif Tissue Int. 2012;91:356–363.
Frei P, Fried M, Hungerbuhler V, et al. Analysis of risk factors for low bone mineral density in inflammatory bowel disease. Digestion. 2006;73:40–46.
Looker AC, Melton LJ 3rd, Borrud LG, et al. Lumbar spine bone mineral density in US adults: demographic patterns and relationship with femur neck skeletal status. Osteoporos Int. 2012;23:1351–1360.
Walldorf J, Krummenerl A, Engler K, et al. Health care for osteoporosis in inflammatory bowel disease: unmet needs in care of male patients? J Crohns Colitis. 1/17/2013 (Epub ahead of print).
Schmidt S, Mellström D, Norjavaara E, et al. Low bone mineral density in children and adolescents with inflammatory bowel disease: a population-based study from Western Sweden. Inflamm Bowel Dis. 2009;15:1844–1850.
Robinson RJ, al-Azzawi F, Iqbal SJ, et al. Osteoporosis and determinants of bone density in patients with Crohn’s disease. Dig Dis Sci. 1998;43:2500–2506.
Bobjer J, Katrinaki M, Tsatsanis C, et al. Negative association between testosterone concentration and inflammatory markers in young men: a nested cross-sectional study. PLoS One. 2013;8:e61466.
Tengstrand B, Hafström I. Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones. J Rheumatol. 2002;29:2299–2305.
Fu YT, Chatur N, Cheong-Lee C, et al. Hypovitaminosis D in adults with inflammatory bowel disease: potential role of ethnicity. Dig Dis Sci. 2012;57:2144–2148.
Ezzat Y, Hamdy K. The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. Int J Rheum Dis. 2010;13:259–265.
Khadgawat R, Makharia GK, Puri K. Evaluation of bone mineral density among patients with inflammatory bowel disease in a tertiary care setting in India. Indian J Gastroenterol. 2008;27:103–106.
Hilmi I, Sunderesvaran K, Ananda V, et al. Increased fracture risk and osteoporosis not associated with vitamin D levels in Malaysian patients with inflammatory bowel disease. J Clin Endocrinol Metab. 2013;98:2415–2421.
Schoon EJ, Blok BM, Geerling BJ, et al. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology. 2000;119:1203–1208.
Del Carmen Navarro M, Saavedra P, Jódar E, et al. Osteoporosis and metabolic syndrome according to socio-economic status; contribution of PTH, Vitamin D and body weight: the Canarian Osteoporosis Poverty Study (COPS). Clin Endocrinol (Oxf). 2013;78:681–686.
Ardizzone S, Bollani S, Bettica P, et al. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn’s disease and ulcerative colitis. J Intern Med. 2000;247:63–70.
Jahnsen J, Falch JA, Mowinckel P, et al. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol. 2004;39:145–153.
Ghosh S, Cowen S, Hannan WJ, et al. Low bone mineral density in Crohn’s disease, but not in ulcerative colitis, at diagnosis. Gastroenterology. 1994;107:1031–1039.
El-Matary W, Sikora S, Spady D. Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. Dig Dis Sci. 2011;56:825–829.
Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med. 1996;239:131–137.
Kaya G, Koçak E, Akbal E, et al. Comparison of the possible risk factors of bone mineral density in subjects with ulcerative colitis and healthy subjects. South Med J. 2011;104:747–751.
Sinnott BP, Licata AA. Assessment of bone and mineral metabolism in inflammatory bowel disease: case series and review. Endocr Pract. 2006;12:622–629.
Kuwabara A, Tanaka K, Tsugawa N, et al. High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporos Int. 2009;20:935–942.
Souza HN, Lora FL, Kulak CA, et al. Low levels of 25-hydroxyvitamin D (25OHD) in patients with inflammatory bowel disease and its correlation with bone mineral density. Arq Bras Endocrinol Metabol. 2008;52:684–691.
Shirazi KM, Somi MH, Rezaeifar P, et al. Bone density and bone metabolism in patients with inflammatory bowel disease. Saudi J Gastroenterol. 2012;18:241–247.
Nakajima S, Iijima H, Egawa S, et al. Association of vitamin K deficiency with bone metabolism and clinical disease activity in inflammatory bowel disease. Nutrition. 2011;27:1023–1028.
Sivagurunathan S, Muir MM, Brennan TC, et al. Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res. 2005;20:390–398.
Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002;109:1041–1048.
Thayu M, Leonard MB, Hyams JS, et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn’s disease: results of the REACH study. Clin Gastroenterol Hepatol. 2008;6:1378–1384.
Ryan BM, Russel MG, Schurgers L, et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn’s disease: a prospective study. Aliment Pharmacol Ther. 2004;20:851–857.
Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn’s disease. J Clin Gastroenterol. 2006;40:55–63.
Veerappan SG, O’Morain CA, Daly JS, et al. Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:1261–1272.
Schulte CM, Dignass AU, Goebell H, et al. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology. 2000;119:909–920.
Etzel JP, Larson MF, Anawalt BD, et al. Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflamm Bowel Dis. 2011;17:2122–2129.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abraham, B.P., Prasad, P. & Malaty, H.M. Vitamin D Deficiency and Corticosteroid Use Are Risk Factors for Low Bone Mineral Density in Inflammatory Bowel Disease Patients. Dig Dis Sci 59, 1878–1884 (2014). https://doi.org/10.1007/s10620-014-3102-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-014-3102-x